EWA
OTLK icon

EverSource Wealth Advisors’s Outlook Therapeutics OTLK Stock Holding History

EverSource Wealth Advisors’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$143 Hold
696
– – ﹤0.01% 4233
2025
Q4 		$1.1K Hold
696
– – ﹤0.01% 3683
2025
Q3 		$738 Sell
696
-126
-15% -$218 ﹤0.01% 3840
2025
Q2 		$1.32K Buy
822
+328
+66% +$523 ﹤0.01% 3658
2025
Q1 		$602 Buy
494
+306
+163% +$537 ﹤0.01% 3401
2024
Q4 		$355 Buy
+188
New +$773 ﹤0.01% 3301

Other funds holding OTLK

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $126M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NMC
Nine Masts Capital Central, Hong Kong $693M AUM 31.93% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return

EverSource Wealth Advisors's OTLK Position: Q1 2026 in Review

EverSource Wealth Advisors held its Outlook Therapeutics (OTLK) position steady in Q1 2026 at 696 shares worth $143. The position accounts for ﹤0.01% of the portfolio, ranked #4233.

EverSource Wealth Advisors first reported a position in OTLK in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.32K in Q2 2025. 54 funds tracked by Wall St. Rank hold OTLK as of Q1 2026.

  • EverSource Wealth Advisors held 696 shares of Outlook Therapeutics worth $143 as of Q1 2026.
  • EverSource Wealth Advisors left its Outlook Therapeutics share count unchanged in Q1 2026.
  • Outlook Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q1 2026, its #4233 holding.
  • EverSource Wealth Advisors first reported a position in Outlook Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • EverSource Wealth Advisors's Outlook Therapeutics position peaked at $1.32K in Q2 2025.
  • 54 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2026.

Based on EverSource Wealth Advisors's 13F filing for Q1 2026, filed 14 May 2026.